title: Anti-CCR4 Monoclonal Antibody Mogamulizumab Followed by the GDP (Gemcitabine, Dexamethasone and Cisplatin) Regimen in Primary Refractory Angioimmunoblastic T-Cell Lymphoma.
abstract: There are few effective options for salvage therapy in elderly patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL). The anti-CCR4 antibody mogamulizumab works via antibody-dependent cytotoxic activity, reduces regulatory T cells, and evokes antitumor immunity in cancer patients. We report a 78-year-old patient with refractory AITL receiving a new immunochemotherapy consisting of sequential mogamulizumab administration followed by the GDP (gemcitabine, dexamethasone and cisplatin) regimen. A favorable consolidative effect of the GDP regimen could be observed in the patient who had partial remission after administration of mogamulizumab monotherapy. The regimen showed an acceptable toxicity profile without serious autoimmunity and an expected treatment response for the elderly patient with primary refractory AITL. This clinical case is the first report of salvage chemotherapy including mogamulizumab for primary refractory AITL described in the literature.
authors.affiliation: Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan.
authors.forename: Harumi
authors.initials: H
authors.lastname: Kato
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Higuchi
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Toko
authors.initials: T
authors.lastname: Saito
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Taji
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Yatabe
authors.forename: Shigeo
authors.initials: S
authors.lastname: Nakamura
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Kinoshita
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003907:Dexamethasone / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D000072281:Lymphadenopathy / Q000175:diagnosis; D008207:Lymphatic Metastasis; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000473:pathology; D054398:Receptors, CCR4 / Q000276:immunology; D016879:Salvage Therapy; D014057:Tomography, X-Ray Computed; D000093542:Gemcitabine
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C515354:CCR4 protein, human; D054398:Receptors, CCR4; D003841:Deoxycytidine; D003907:Dexamethasone; D002945:Cisplatin; C549035:mogamulizumab; D000093542:Gemcitabine